证券代码：688578 证券简称：艾力斯 公告编号：2024-011 上海艾力斯医药科技股份有限公司 关于确定原募投项目剩余募集资金用途、部分募投项目结 项并将节余募集资金用于新药研发项目及补充流动资金、 调整新药研发项目的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 上海艾力斯医药科技股份有限公司（以下简称"公司"或"艾力斯"）于 2024 年 4 月 24 日召开第二届董事会第八次会议、第二届监事会第七次会议，审 议通过了《关于确定原募投项目剩余募集资金用途的议案》、《关于部分募投项目 结项并将节余募集资金用于新药研发项目及补充流动资金的议案》、《关于调整新 药研发项目的议案》，同意确定原募投项目"药物研究分析检测中心项目"剩余 的募集资金全部用于投入"新药研发项目"；同意将募投项目"总部及研发基地 项目"、"营销网络建设项目"以及"信息化建设项目"予以结项，并将结项的节 余募集资金部分用于"新药研发项目"、部分用于补充流动资金；同意调整"新 药研发项目"子项目及部分子项目的投资金额。公司保荐机构中信证券股份有 ...

证券代码：688578 证券简称：艾力斯 公告编号：2024-009 一、利润分配方案内容 经普华永道中天会计师事务所（特殊普通合伙）审计，上海艾力斯医药科技 股份有限公司（以下简称"公司"）2023 年度合并财务报表归属于上市公司股东 的净利润为人民币 644,174,819.25 元，截至 2023 年 12 月 31 日，母公司报表期 末未分配利润为人民币 314,910,229.17 元。经董事会决议，公司 2023 年年度拟 以实施权益分派股权登记日登记的总股本为基数分配利润。本次利润分配方案如 下： 公司拟向全体股东每 10 股派发现金红利 4.0 元（含税）。截至 2023 年 12 月 31 日，公司总股本 450,000,000 股，以此计算合计拟派发现金红利 180,000,000.00 元（含税）。本年度公司现金分红比例占合并报表中归属于上市公司股东的净利 1 每股分配比例：每 10 股派发现金红利人民币 4.0 元（含税）。公司不送红股， 不进行资本公积金转增股本。 本次利润分配以实施权益分派股权登记日登记的总股本为基数，具体日期将 在权益分派实施公告中明确。 在实施权益分派的股权登记 ...

Financial Performance - The company's revenue for Q1 2024 reached ¥742,835,715.09, representing a year-on-year increase of 168.65%[4] - Net profit attributable to shareholders was ¥306,052,559.16, showing a significant increase of 777.51% compared to the same period last year[4] - The net profit after deducting non-recurring gains and losses was ¥301,141,732.04, reflecting a remarkable increase of 1,423.83% year-on-year[4] - Basic and diluted earnings per share were both ¥0.68, marking a substantial increase of 750.00% compared to the previous year[4] - The company achieved operating revenue of RMB 743 million in Q1 2024, a significant increase of 168.65% compared to the same period last year[12] - Net profit attributable to the parent company reached RMB 306.05 million, marking a substantial growth of 777.51% year-over-year[12] - The net profit attributable to the parent company after deducting non-recurring gains and losses was RMB 301.14 million, reflecting an impressive increase of 1,423.83% compared to the previous year[12] - Operating profit for Q1 2024 was CNY 313,917,428.44, compared to CNY 36,685,177.03 in Q1 2023, indicating a substantial increase of about 757.5%[19] - Net profit for Q1 2024 was CNY 306,052,559.16, up from CNY 34,877,411.06 in Q1 2023, reflecting an increase of approximately 775.5%[19] - The company reported a total comprehensive income of CNY 320,044,154.27 for Q1 2024, compared to CNY 34,174,103.40 in Q1 2023, indicating a growth of about 836.5%[19] Assets and Liabilities - The company's total assets at the end of the reporting period were ¥4,376,495,351.66, an increase of 7.40% from the end of the previous year[4] - As of March 31, 2024, total assets amounted to RMB 4.70 billion, an increase from RMB 4.38 billion at the end of 2023[16][17] - The company's cash and cash equivalents stood at RMB 2.40 billion, up from RMB 1.86 billion at the end of 2023[16] - Total liabilities decreased to RMB 379.72 million from RMB 394.22 million at the end of 2023[17] - The equity attributable to the parent company increased to RMB 4.32 billion, compared to RMB 3.98 billion at the end of 2023[17] - Cash and cash equivalents at the end of Q1 2024 totaled CNY 1,919,566,295.01, compared to CNY 374,809,250.57 at the end of Q1 2023, marking an increase of approximately 412.5%[22] Research and Development - Research and development expenses totaled ¥64,126,011.92, accounting for 8.63% of revenue, which is a decrease of 14.35 percentage points year-on-year[4] - Research and development expenses for Q1 2024 were CNY 64,126,011.92, slightly up from CNY 63,535,586.23 in Q1 2023, showing a marginal increase of 1%[18] - The company has received approval for the Phase I clinical trial of its self-developed KRAS G12D selective inhibitor, AST2169, which addresses a significant unmet clinical need[14] Shareholder Information - The top shareholder, Shanghai Qiaoke Enterprise Development Co., Ltd., holds 32.17% of the shares, with a total of 144,776,786 shares[9] - The company has a strong shareholder base, with the top 10 shareholders holding significant stakes, including Chen Xiaofa with 6,721,880 shares[11] Government Support - The company received government subsidies amounting to ¥1,325,609.20 during the reporting period[6] Product Performance - The increase in net profit was primarily driven by a substantial rise in sales of the drug Fumeitini, which was included in the medical insurance list this year[8] - The core product, Furmetin, has been included in the national medical insurance directory, which is expected to positively impact sales performance in 2024[13]

Financial Performance - The company has not achieved profitability since its listing [3]. - The company reported a revenue of RMB 1.5 billion for the fiscal year 2023, representing a year-over-year growth of 20% [11]. - The company reported a significant increase in revenue, achieving a total of 1.2 billion CNY, representing a 25% growth year-over-year [15]. - The total operating revenue for 2023 was CNY 2,018,182,563.12, an increase of 155.14% compared to the previous year, primarily due to the inclusion of the core product, Furmonertinib tablets, in the national medical insurance directory, leading to a significant increase in sales volume [23]. - The net profit attributable to shareholders of the parent company reached CNY 644,174,819.25, representing a growth of 393.54% year-on-year, driven by substantial revenue growth and effective cost control [23]. - The net cash flow from operating activities was CNY 674,649,764.32, an increase of 636.28% compared to the previous year [21]. - Basic earnings per share for 2023 were CNY 1.43, up 393.10% from CNY 0.29 in 2022 [22]. - The company reported a total of CNY 37,990,536.06 in non-recurring gains and losses for 2023 [26]. - The company experienced a significant increase in quarterly revenue, with Q4 2023 revenue reaching CNY 670,380,800.29, marking a continuous growth trend throughout the year [25]. - The company achieved total revenue of 2,018.18 million yuan, a year-on-year increase of 155.14% [29]. - The net profit attributable to the parent company was 644.17 million yuan, up 393.54% year-on-year, while the net profit excluding non-recurring gains and losses reached 606.18 million yuan, reflecting a 663.70% increase [29]. Research and Development - Research and development expenses amounted to CNY 313,059,372.61, a 63.26% increase year-on-year, but the proportion of R&D expenses to operating revenue decreased to 15.51%, down 8.73 percentage points from the previous year [23]. - The company is advancing its research and development efforts, with three new drug applications (NDA) expected to be submitted in the next 12 months [14]. - The company has a robust pipeline with multiple new drug candidates in clinical and preclinical stages, including a fourth-generation EGFR-TKI and PRMT5 inhibitors [39][40]. - The company is conducting multiple clinical trials to explore Furmonertinib's clinical advantages, including a Phase III trial for adjuvant therapy in EGFR mutation-positive NSCLC patients [51]. - The company has developed AST2169, a selective inhibitor for KRAS G12D mutations, which are found in approximately 30% of pancreatic cancer cases, 12% of colorectal cancer cases, and 4% of non-small cell lung cancer cases [54]. - The company is also developing a next-generation EGFR oral small molecule inhibitor (ABK3376), currently in the preclinical stage, with a total investment of approximately ¥2.32 million [84]. - The company’s R&D efforts are focused on achieving best-in-class and first-in-class drug candidates through its core technologies in drug design and optimization [78]. - The company has established a GMP-compliant production facility to ensure effective supply of Furmonertinib [90]. Market Expansion and Strategy - The company plans to expand its market presence in Southeast Asia, targeting a 15% market share by the end of 2025 [11]. - Market expansion plans include entering two new international markets by Q3 2024, targeting a 15% market share in those regions [15]. - The company is exploring potential acquisitions to enhance its product portfolio, with a budget of 200 million CNY allocated for this purpose [15]. - A strategic acquisition of a biotech firm was completed, enhancing the company's R&D capabilities in oncology [12]. - The company signed a collaboration agreement to obtain exclusive commercialization rights for Pralsetinib capsules in mainland China, which is the first approved RET inhibitor in the region [52]. - The company is actively expanding Furmonertinib's clinical indications through ongoing clinical trials for various patient populations, including those with CNS metastases and rare mutations [51]. Corporate Governance - The company has received a standard unqualified audit report from PwC Zhong Tian [4]. - The company does not have any special arrangements for corporate governance [4]. - The board of directors has fully attended the board meeting [4]. - The company has established various committees under the board, including audit, compensation, and strategy committees, to enhance governance efficiency [147]. - The company has a performance management system in place for senior management, which includes setting clear goals and conducting regular evaluations [200]. - The company has established employee stock ownership plans and other incentive measures to align employee interests with company performance [199]. Risk Factors - The company has detailed various risk factors in its annual report, which can be found in the "Management Discussion and Analysis" section [4]. - The company faces risks related to reliance on a single product and potential market competition, which could affect financial performance [93]. - The company is exposed to regulatory risks due to the highly regulated nature of the pharmaceutical industry, which may affect operational strategies [97]. - The company faced risks related to potential adjustments in the National Medical Insurance Directory, which could impact the market share and sales revenue of Furmonertinib [96]. Employee Development - The company is focused on talent development, implementing a structured training program to enhance employee skills and support sustainable growth [35]. - The company has implemented a digital learning platform, "Aixuetang," to enhance employee training and development [187]. - The company launched an AI coaching system, "Aijiaolian," in 2023 to improve employees' professional knowledge and core information transmission capabilities [187]. - The company has a training system that includes professional courses, general skills courses, and leadership courses for employees at all levels [186]. Profit Distribution - The proposed profit distribution plan for 2023 includes a cash dividend of 4.00 CNY per 10 shares, totaling 180,000,000 CNY, which represents 27.94% of the net profit attributable to shareholders [5]. - The company has established a cash dividend policy, ensuring that at least 10% of the distributable profit is allocated as cash dividends if there are no major investment plans or expenditures [190]. - The cash dividend distribution policy requires a minimum of 80% payout for mature companies without significant capital expenditure plans, and 40% if there are significant expenditures [191]. - The profit distribution proposal must be approved by more than half of the board members before being submitted to the shareholders' meeting for review [192]. - The company engages in regular communication with shareholders, especially minority shareholders, to gather their opinions before the profit distribution plan is reviewed [192].

上海艾力斯医药科技股份有限公司（以下简称"公司"）于 2024 年 4 月 24 日召开了第二届董事会第八次会议，审议通过了《关于调整第二届董事会审计委 员会委员的议案》。具体情况如下： 根据中国证券监督管理委员会发布的《上市公司独立董事管理办法》有关规 定，审计委员会成员应当为不在上市公司担任高级管理人员的董事。为完善公司 治理结构，保障公司董事会审计委员会规范运作，结合公司实际情况，公司董事 会同意对第二届董事会审计委员会部分委员进行调整，公司董事长兼总经理杜锦 豪先生不再担任公司第二届董事会审计委员会委员。董事会选举祁菊女士担任第 二届董事会审计委员会委员，与严骏先生（主任委员）、阳佳余女士共同组成公 司第二届董事会审计委员会，任期自董事会审议通过之日起至第二届董事会任期 届满之日止。 特此公告。 上海艾力斯医药科技股份有限公司董事会 2024 年 4 月 26 日 1 证券代码：688578 证券简称：艾力斯 公告编号：2024-014 上海艾力斯医药科技股份有限公司 关于调整第二届董事会审计委员会委员的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容 ...

第二章 独立董事任职资格 上海艾力斯医药科技股份有限公司 独立董事工作制度 第一章 总则 1 第一条 为完善上海艾力斯医药科技股份有限公司(以下简称"公司")治理结 构, 促进公司规范运作, 维护公司和股东的利益, 根据《中华人民共 和国公司法》(以下简称"《公司法》")、《上市公司独立董事管理办法》 (以下简称"《独立董事管理办法》")以及《上海艾力斯医药科技股份 有限公司章程》(以下简称"公司章程")的有关规定, 并结合公司实 际情况, 制定本制度。 第二条 独立董事是指不在公司担任除董事外的其他职务, 并与其所受聘的 公司及其主要股东、实际控制人不存在直接或者间接利害关系, 或者 其他可能妨碍其进行独立客观判断的关系的董事。 第三条 独立董事对公司及全体股东负有忠实与勤勉义务。独立董事应当按照 有关法律、行政法规、规范性文件、中国证券监督管理委员会(以下 简称"中国证监会")规定、证券交易所业务规则和公司章程的要求, 认 真履行职责, 维护公司整体利益, 尤其要关注中小股东的合法权益不 受损害。 第四条 独立董事应当独立履行职责, 不受公司主要股东、实际控制人或者其 他与公司存在利害关系的单位或个人的影 ...

上海艾力斯医药科技股份有限公司全体股东： 根据《企业内部控制基本规范》及其配套指引的规定和其他内部控制监管要求（以下简称企业内部 控制规范体系），结合本公司（以下简称公司）内部控制制度和评价办法，在内部控制日常监督和专项 监督的基础上，我们对公司2023年12月31日（内部控制评价报告基准日）的内部控制有效性进行了评价。 一. 重要声明 按照企业内部控制规范体系的规定，建立健全和有效实施内部控制，评价其有效性，并如实披露内 部控制评价报告是公司董事会的责任。监事会对董事会建立和实施内部控制进行监督。经理层负责组织 领导企业内部控制的日常运行。公司董事会、监事会及董事、监事、高级管理人员保证本报告内容不存 在任何虚假记载、误导性陈述或重大遗漏，并对报告内容的真实性、准确性和完整性承担个别及连带法 律责任。 公司内部控制的目标是合理保证经营管理合法合规、资产安全、财务报告及相关信息真实完整，提 高经营效率和效果，促进实现发展战略。由于内部控制存在的固有局限性，故仅能为实现上述目标提供 合理保证。此外，由于情况的变化可能导致内部控制变得不恰当，或对控制政策和程序遵循的程度降低， 根据内部控制评价结果推测未来内部控制 ...

中信证券股份有限公司关于 上海艾力斯医药科技股份有限公司 2023 年度募集资金存放与使用情况的专项核查意见 中信证券股份有限公司（以下简称"中信证券"或"保荐机构"）作为上海 艾力斯医药科技股份有限公司（以下简称"艾力斯"或"公司"）首次公开发行 股票并上市的持续督导保荐机构，根据《中华人民共和国公司法》《中华人民共 和国证券法》《上市公司监管指引第 2 号——上市公司募集资金管理和使用的监 管要求（2022 年修订）》《上海证券交易所科创板上市公司自律监管指引第 1 号 ——规范运作（2023 年 12 月修订）》等有关规定，对艾力斯 2023 年度募集资 金的存放和使用情况进行了专项核查，核查情况如下： 一、募集资金基本情况 （一）实际募集资金的金额及到账情况 （二）募集资金本报告期内使用金额及期末余额情况 截至 2023 年 12 月 31 日，募集资金账户余额为人民币 661,768,228.81 元， 本公司本年度使用募集资金人民币 191,878,784.64 元，本年度使用超募资金永久 补充流动资金 人民 币 44,159,621.59 元，累计使用募 集资 金总额人民币 1 1,239,81 ...

上海艾力斯医药科技股份有限公司 募集资金管理制度 第一章 总则 第二章 募集资金专户存储 第五条 募集资金应当存放于董事会决定的专项账户(以下简称"专户")集中管理。 募集资金专户不得存放非募集资金或用作其它用途。 1 第一条 为加强、规范上海艾力斯医药科技股份有限公司(以下简称"公司")募集资金 的管理, 提高募集资金使用效率和效益, 根据《中华人民共和国公司法》《中 华人民共和国证券法》《上海证券交易所科创板上市公司自律监管指引第 1 号——规范运作》等法律法规和规范性文件, 以及《上海艾力斯医药科技股份 有限公司章程》(以下简称"《公司章程》")的规定, 结合公司实际情况, 特 制定本制度。 第二条 募集资金是指本公司通过公开发行证券(包括首次公开发行股票、配股、增发、 发行可转换公司债券、发行分离交易的可转换公司债券等)以及非公开发行证 券向投资者募集的资金, 但不包括上市公司实施股权激励计划募集的资金。 第三条 公司董事、监事和高级管理人员应对募集资金的管理和使用勤勉尽责。在公开 募集前, 应根据公司发展战略、主营业务、市场形势和国家产业政策等因素, 对募集资产拟投资项目可行性进行充分论证, 明确拟 ...

上海艾力斯医药科技股份有限公司董事会 2023 年度关于独立董事独立性评估的专项意见 根据证监会《上市公司独立董事管理办法》《上海证券交易所科创板股 票上市规则》《上海证券交易所科创板上市公司自律监管指引第 1 号——规 范运作》等相关要求，上海艾力斯医药科技股份有限公司（以下简称"公司"） 董事会，就公司独立董事阳佳余、吕超、严骏、朱圣韬的独立性情况进行评 估并出具如下专项意见： 经核查公司独立董事阳佳余、吕超、严骏、朱圣韬的兼职、任职情况以 及其签署的独立性自查情况报告，上述人员除在公司担任独立董事及董事 会专门委员会委员外，不存在在公司任职以及在公司主要股东单位任职的 情形，与公司以及主要股东之间不存在利害关系、重大业务往来或其他可能 妨碍其独立性的关系。因此，董事会认为公司独立董事符合《上市公司独立 董事管理办法》《上海证券交易所科创板上市公司自律监管指引第 1 号—— 规范运作》中对独立董事独立性的相关要求。 上海艾力斯医药科技股份有限公司董事会 2024 年 4 月 24 日 ...